gewrichtaandoening degenerative arthritis degenerative joint disease
Conditions
Interventions
Hydroxychloroquine 400 mg or placebo capsule QD for 24 weeks.
Sponsors
Maasstadziekenhuis
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Age * 40 years Primary hand OA according to the ACR classification Heberden or Bouchard nodule or Kellgren-Lawrence grade 1, 2 or 3 in * 2 symptomatic joints Pain in the dominant hand * 12 months Use of an NSAID for * 1 episode of pain Written informed consent
Exclusion criteria
Exclusion criteria: Secondary hand OA, e.g. hemochromatose, rheumatoid arthritis, posttraumatic Kellgren-Lawrence grade 4 OA Use of hydroxychloroquine within 3 months before entering the study Use of NSAIDs or corticosteroids within 7 days before entering the study Retinopathy Myastenia Gravis Known allergy or hypersensitivity for hydroxychloroquine
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain intensity at week 24 (100 mm VAS) compared to baseline | — |
Secondary
| Measure | Time frame |
|---|---|
| Hand function at week 24 (AUSCAN and AIMS2-SF) compared to baseline Pain intensity at week 6 and 12 compared to baseline Radiographic progression at week 24 | — |
Countries
Netherlands
Outcome results
None listed